“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
Monocrotaline-induced pulmonary hypertension
Purpose
To assess the effect of antihypertensive agents on pulmonary artery pressure and right ventricular hypertrophy
Method
Single injection of monocrotaline (MCT); a pyrrolizidine alkaloid which leads to endothelial dysfunction and damage associated with clinical pathogenesis of PAH in human. Severe PAH is observed after 28 days following the MCT injection.
Study Outcome
- Hemodynamic parameters; mPAP, mSAP, RVSP, Pulse Pressure, PVR, Heart rate, saturation
- Fulton’s index, Lung weight
- Cardiac function parameters obtained by echocardiography; CO, SV, PAAT, Vmax, VTI, RV free wall thickness
Compliance
Non-GLP
Species
Rats
Scientist Director
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
Analysis & guidance included. Always.
Contact us to learn more about how IPST customizes each study design to maximize your strategic and scientific ROI.
Let’s talk
Let’s talk
At IPST we believe each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated. We believe in taking ownership of the studies entrusted to IPST while ensuring mutual collaboration for developing and agreeing to overall project plans.
Contact us